Skip to main content

A Phase 2, multi-center, randomized, double blind, placebo controlled study in subjects with late prodromal and early manifest Huntington Disease )HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503

Clinical Trial Grant
Duke Scholars

Administered By

Neurology, Movement Disorders

Awarded By

Vaccinex, Inc.

Start Date

July 1, 2015

End Date

December 31, 2021
 

Administered By

Neurology, Movement Disorders

Awarded By

Vaccinex, Inc.

Start Date

July 1, 2015

End Date

December 31, 2021